Linezolida Accordpharma (Linezolid)

Linezolid is indicated for a range of serious Gram‑positive bacterial infections, particularly those resistant to other agents.

• Skin and soft‑tissue infections: effective against MRSA and other susceptible Gram‑positive organisms.
• Community‑acquired pneumonia: provides coverage for typical and atypical pathogens resistant to β‑lactams.
• Hospital‑acquired pneumonia: treats severe infections where MRSA or VRE are suspected.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates resistant strains in skin, lung and bloodstream sites.
• Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative option for resistant enterococcal disease.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This binding prevents the formation of the initiation complex, halting translation of essential proteins and thereby exerting a bacteriostatic effect against susceptible Gram‑positive organisms. The drug’s unique binding site is not shared by other antibiotic classes, which reduces cross‑resistance. By maintaining the ribosomal conformation, linezolid blocks the positioning of transfer RNA, leading to inhibition of peptide chain elongation.

Linezolid may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset that often resolves without intervention.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste perception during therapy.
• Vomiting: occasional emesis, usually mild.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count requiring monitoring.
• Peripheral neuropathy: sensory disturbances that may be irreversible.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
• Optic neuritis: vision changes that necessitate immediate evaluation.
• Lactic acidosis: rare metabolic disturbance with high morbidity.

When using Linezolida Accordpharma, clinicians should consider several safety measures.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: assess liver enzymes regularly during prolonged treatment.
• Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome.
• Prolonged therapy: perform periodic complete blood counts to detect hematologic effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs): increased risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): heightened serotonin toxicity.
• Rifampicin: may markedly reduce linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: potential elevation of INR, requiring coagulation monitoring.
• Phenytoin: may lower linezolid levels, affecting efficacy.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased bleeding tendency when combined with thrombocytopenia.